CDXS vs TMO
CDXS: Codexis utilizes proprietary directed evolution and machine learning to engineer high-performance enzymes that optimize the manufacturing of complex RNAi and small molecule therapeutics. TMO: A massive, diversified life sciences conglomerate providing the essential infrastructure, tools, and services that enable scientific research and global healthcare diagnostics.
Side-by-side fundamentals
| Metric | CDXS | TMO | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $1.40 | $574.30 | |
| Market cap as of 2026-08-03 | $127M | $212.3B | |
| P/E as of 2026-08-03 | n/a | 30.92 | |
| PEG as of 2026-08-03 | n/a | 3.39 | |
| Net margin as of 2026-08-03 | -41.0% | +15.0% | TMO higher |
| Gross margin as of 2026-08-03 | +88.9% | +40.9% | CDXS higher |
| Operating margin as of 2026-08-03 | -37.5% | +17.6% | TMO higher |
| ROE as of 2026-08-03 | -68.1% | +13.3% | TMO higher |
| ROA as of 2026-08-03 | -23.7% | +6.3% | TMO higher |
| Debt / equity as of 2026-08-03 | 0.94 | 0.81 | TMO lower |
| Revenue growth (YoY) as of 2026-08-03 | +56.8% | +7.2% | CDXS higher |
| Revenue CAGR (3y) SEC XBRL | -20.2% | -0.3% | TMO higher |
| Dividend yield as of 2026-08-03 | n/a | +0.3% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-03 | 1.77 | 0.75 | |
| 1-year return as of 2026-07-31 close | -47.8% | +22.8% | TMO higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.